NewsRoom Articles - Page 109 of 154 - PsychedelicNewsWire (PNW)

WednesdayJan 13, 2021 2:15 pm

Research Shows Ketamine Helps Major Depressive Disorder Patients Adjust How They Perceive Reality

New research indicates that brain signals that are linked to neural plasticity may be used to explain the quick antidepressant effects that ketamine possesses. The research findings, which were reported in the “European Neuropsychopharmacology” journal, show that ketamine may help reduce depression by overriding an individual’s insensitivity to prediction error. Lead researcher Rachael Sumner explained that ketamine had the potential to not only treat but also help researchers understand depression better. This is mainly because ketamine works differently when compared to ordinary antidepressants. Sumner, who is a School of Pharmacy postdoctoral research fellow from the University of Auckland, explained that…

TuesdayJan 12, 2021 2:00 pm

Could Canada Be the Next Country to Legalize Psychedelics?

Canada has made significant strides in its health policies, having allowed psychedelics to be administered to four cancer patients in their end-of-life treatments, and established and implemented a health-care program that’s publicly funded, in addition to becoming the first G7 nation to legalize marijuana in 2018. While there’s a lot the country can be commended for, some of the regulations that govern restricted substances are out-of-date. In a bid to change that, a few patients along with therapists and doctors have been allowed to use psilocybin, with the country’s federal agency looking into amending some of the existing policies, which…

TuesdayJan 12, 2021 11:04 am

Health Canada Grants Selected Physicians Access to Psilocybin Mushrooms as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Dives into Functional Mushroom Market

Health Canada recently granted psilocybin testing access to selected physicians Psilocybin mushrooms shown to help patients suffering from addiction, mental health issues Pure Extracts’ ’Pure Mushrooms’ and ‘Pure Pulls’ branded products expected to be available by end of Q1 2021 In a recent virtual townhall, Canadian Health Minister Patty Hajdu disclosed that the Canadian government has recently granted access to psilocybin or “psychedelic” mushrooms to several physicians for use in patients with addiction and/or mental health issues (https://ibn.fm/j9ZAO). In line with anticipated legislation expected to loosen restrictions on psilocybin mushrooms, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a Canadian…

MondayJan 11, 2021 2:30 pm

Johns Hopkins Researchers Study Ideal Music for Psychedelic Therapy Sessions

Researchers from the Johns Hopkins University School of Medicine recently discovered that playing classical music during a psychedelic therapy session added no value to the session. So while Bach or Chopin may be calming to listen to, they are of no special value in the therapy room. The study also discovered that gongs would be better suited for such an exercise. The researchers noted in the study that while Western classical music was assumed to be the norm in psychedelic therapy, the data collected during the study challenged the belief that any genre of music would support an individual’s psychedelic…

FridayJan 08, 2021 10:30 am

Innovative Canadian Psychedelics Company Files Another US Patent Application

Towards the end of last year, Mindset Pharma Inc. (CSE: MSET) a psychedelic-based, drug-discovery company that creates new psychedelic compounds to help manage treatment-resistant neurological and psychiatric disorders, announced that it had filed a provisional patent application with the U.S. Patent and Trademark Office. The company began trading on the Canadian Securities Exchange last year. Under the latest patent application, the company has synthesized new tryptamine compounds. This has increased the number of potential drug candidates under the firm’s new drug-discovery and development program to 50. Mindset CEO James Lanthier stated that the data generated by the company’s pre-clinical program…

ThursdayJan 07, 2021 11:25 am

Functional Mushroom Market Set to Grow in Coming Years

In 2020, functional mushrooms successfully transitioned from the wellness pipeline into the mainstream market, with more opportunities set to open up as many anticipate extensive psychedelic legalization. Oregon legalizing the use of psilocybin mushrooms, a psychedelic, for therapeutic use and the potential and health benefits of these mushrooms are good signs. People looking to consume adaptogens can find mushrooms in literally anything, including jerky, supplements, tea and coffee as well as beauty products. The functional mushroom market on a global scale was valued at $23 billion last year. The forecasted compound yearly growth rate is said to be 5.6% over…

WednesdayJan 06, 2021 2:15 pm

2020: A Bad Year for the Global Economy, a Good Year for the Psychedelics Industry

Last year was a good year for many psychedelic companies and psychedelics in general, as they went mainstream, with many substances being studied for the potential to treat various mental health conditions. Various psychedelic companies — those dealing with production as well as research — moved into investment markets, with roughly 24 companies going public between February and December 2020. The first among these was Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF), which became the first psychedelics firm to debut an IPO in Canada, launching March 3 on the NEO exchange. Canada’s conducive environment for small-cap venture investment set up…

WednesdayJan 06, 2021 1:59 pm

Pure Extracts Technologies (CSE: PULL) Draws Out Expansion Plans in Anticipation of Regulatory Changes Within Mushroom Sector

Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled substances and carry out research into psychedelic compounds such as psilocybin and psilocin – paving way towards future commercialization of its product The Dealer’s License application has taken on increased relevance following Health Canada’s decision to revise existing regulations to permit certain authorized uses of…

TuesdayJan 05, 2021 1:01 pm

Cybin Inc. (NEO: CYBN) R&D Sees Hope in Growing Acceptance of Psilocybin

U.S. taking actionable steps toward acceptance of psilocybin States, individual cities have decriminalized, made use and possession of psilocybin low law-enforcement priority More psilocybin research being done focused on health, well-being of Americans facing a mental health crisis on epic levels Cybin (NEO: CYBN) is a life science company focused on the pharmaceutical development of psychedelic products. The company's subsidiary Serenity Life Sciences is focused on the research and development of psilocybin-based medications. Psilocybin, referred to by the media as magic mushrooms, has had its share of bad press. The stigma of this substance has halted R&D in America in…

TuesdayJan 05, 2021 9:30 am

Research Suggests That Single Dose of Psychedelics May Alleviate Racial Injustice Trauma

A recent study has suggested that one positive experience on a psychedelic medicine may help alleviate anxiety, depression and stress symptoms in Indigenous and Black people as well as people of color who have been affected by racism. The retrospective study involved 30 participants who admitted that in the 30 days following an experience with either ecstasy (“MDMA”), psilocybin mushrooms or LSD, the trauma-related symptoms they experienced that were connected with acts of racism were reduced. Ohio State University assistant professor of social work Alan Davis, who was also a co-lead author of the study, explained that the participants’ experience…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000